Programme Benefits

End Stage Renal Disease (ESRD) is an irreversible kidney damage that adds a heavy strain on the global healthcare system. Taiwan, which has the highest prevalence of global ESRD, spends an astonishing 7.85% of its total national healthcare budget on the ESRD population, which accounts for a mere 0.3% of its population. Similarly, in US, the number of ESRD patients constitute 1% of the Medicare population, but consumes 7% of the entire Medicare budget. In 2015 alone, the fiscally demanding cure to this disease cost an annual expenditure of US$ 69.45B. For a disease that has a Compound Annual Growth Rate (CAGR) of 6.2%, this is compelling evidence that ESRD urgently requires innovative measures to improve clinical outcomes and lighten financial burdens to global healthcare systems.


As designated step-down institutions where patients visit thrice three times a week, dialysis centres are responsible for specialized renal care provided to the patient. With the global renal manpower shortage, the value proposition for them to adopt NephTech Surveillance Program is compelling:

Who We Benefits





image

Dialysis Centres
image

End Stage RenalDisease
Patients
image

National Healthcare System
image

Government
image

Insurers